[{"Assets_0_Q2_USD":1129483000.0,"CommonStockSharesOutstanding_0_Q2_shares":46603839.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-78706000.0,"NetIncomeLoss_1_Q2_USD":-16978000.0,"NetIncomeLoss_2_Q2_USD":-91576000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":46541716.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":45439666.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":46541716.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":45439666.0,"StockholdersEquity_0_Q2_USD":1077763000.0,"Ticker":"SAGE","CIK":"1597553","name":"SAGE THERAPEUTICS, INC.","OfficialName":"Sage Therapeutics Inc. Common Stock","form":"10-Q","period":"20180630","fy":"2018.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"2034401653.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20180807"}]